Merck's Zilovertamab Vedotin Shows 100% Response Rate in Lymphoma Trials Progressing to Phase III
Merck has reported promising results in its lymphoma trials, marking a significant milestone with zilovertamab vedotin, which achieved a 100% complete response rate in patients with diffuse large B-cell lymphoma (DLBCL) at a dose of 1.75 mg/kg when combined with the R-CHP regimen[1][2]. The investigational antibody-drug conjugate targets the ROR1 protein on cancer cells, thereby arresting cell division and causing cell death[1]. Though some higher dose regimens showed fluctuating response rates, the decision to advance the low-dose cohort to a Phase III trial underscores Merck’s commitment to effective and safer cancer treatments[1][2]. The Phase III trial will mainly focus on progression-free survival while also analyzing complete response and overall survival, providing further insights as the competition in ADC development intensifies[2].
References
Explore Further
What are the potential long-term effects that Merck anticipates in patients using zilovertamab vedotin for diffuse large B-cell lymphoma in Phase III trials?
How does zilovertamab vedotin's approach to targeting the ROR1 protein differ from other antibody-drug conjugates currently being developed by competitors?
What measures is Merck implementing to mitigate the safety concerns observed at higher doses of zilovertamab vedotin?
In what ways might the success of zilovertamab vedotin in clinical trials impact the broader antibody-drug conjugate market for lymphoma treatment?
How does the progression-free survival endpoint in the Phase III trials for zilovertamab vedotin compare with the standard R-CHOP regimen in terms of expected outcomes?